Epsilon Healthcare (ASX:EPN) has successfully renewed a medicinal cannabis permit for its wholly owned operating subsidiary, THC Pharma (ASX:THC).

The Office of Drug Control (ODC) has granted Epsilon increased manufacturing quantities to meet the growing demand from its clients, as demonstrated by a ramp-up in activities reported for the 2022 period.

Epsilon says it is proud of the progress made so far, along with the increase in the manufacturing quantities granted by ODC, due to increased client demand.

Additionally, the company says it is continuing to deliver its clients and patients with the ‘highest’ quality medicines possible and an ‘exceptional’ level of care.

Epsilon Health is an ASX-listed diversified global healthcare and pharmaceuticals company, which owns a number of medicinal cannabis assets including the largest GMP cannabis manufacturing facility in the Southern Hemisphere and the Tetra Health Clinic Group.